Company Profile
Pulse Biosciences Stock Price, News & Analysis
- Ticker:
- PLSE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
38.24 USD (+0.90%)
Close
Last updated: August 6, 2026
1.68B USD
Market cap
Why the stock is moving
The latest monitored company update is “Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.
Company overview
Nanosecond Pulsed-Field Ablation
Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications.
Cardiac Catheter System
The nPulse Cardiac Catheter System is being developed for catheter-based treatment of atrial fibrillation. European feasibility data showed durable procedural success, and the U.S. NANOPULSE-AF pivotal IDE trial has begun enrolling patients.
Surgical Atrial Fibrillation
Pulse is also developing an nPulse surgical system for concomitant atrial-fibrillation ablation during cardiac surgery. A separate IDE pivotal trial is intended to support regulatory review in this procedural setting.
Thyroid Applications
The company is studying nanosecond PFA for benign thyroid nodules and papillary thyroid microcarcinoma. Early benign-nodule data showed durable volume reduction, while a first-in-human cancer feasibility study is underway with MD Anderson.
Future catalysts
Completion of enrollment in the NANOPULSE-AF cardiac-catheter pivotal trial anticipated in early fourth-quarter 2026.
Completion of enrollment in the papillary thyroid microcarcinoma feasibility study expected by year-end 2026.
Completion of enrollment in the surgical atrial-fibrillation IDE pivotal trial expected by the end of the first half of 2027.
Recent news
- 01
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
Source: Pulse Biosciences
- 02
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
Source: Pulse Biosciences
- 03
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
Source: Pulse Biosciences
- 04
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
Source: Pulse Biosciences
- 05
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Pulse Biosciences
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pulse Biosciences (PLSE)?
Pulse Biosciences (PLSE) most recently closed at 38.24 USD, a +0.90% move versus the previous session.
What is the market cap of Pulse Biosciences (PLSE)?
Pulse Biosciences currently has a market capitalization of 1.68B USD on BioPharmSignal.
What does Pulse Biosciences do?
Nanosecond Pulsed-Field Ablation Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications. Cardiac Catheter System The nPulse Cardiac Catheter System is...
On which exchange is PLSE stock listed?
Pulse Biosciences (PLSE) is associated with NASDAQ, United States, Biopharma.
What is NANOPULSE-AF?
Completion of enrollment in the NANOPULSE-AF cardiac-catheter pivotal trial anticipated in early fourth-quarter 2026.
Which conditions is Pulse Biosciences targeting with NANOPULSE-AF?
Pulse Biosciences is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Pulse Biosciences describe recent progress with NANOPULSE-AF?
Completion of enrollment in the NANOPULSE-AF cardiac-catheter pivotal trial anticipated in early fourth-quarter 2026.
What is Nanosecond?
Nanosecond Pulsed-Field Ablation Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue.